The effects of selective CC chemokine receptor (CCR)-3 antagonists on antigen-induced leukocyte accumulation in the lungs of mice adoptively transferred with in vitro-differentiated
Introduction
The crucial contribution of T h 2 to the development of allergic eosinophilic inflammation has been established (1) . Accumulating evidence suggests that CC chemokine receptor (CCR)-3 plays a critical role in the accumulation of eosinophils as well as T cells during allergic inflammation (2) (3) (4) . Enhanced expression of CCR3 and its ligands has been recognized in bronchial asthma (5) . Gene disruption and/or blockade of CCR3 as well as its ligand, CC chemokine ligand (CCL)-11, resulted in a reduction of eosinophilic infiltration in animal models of asthma (6) (7) (8) (9) .
However, the contribution of CCR3 to allergic diseases remains controversial in view of the apparently contradictory findings that substantial eosinophilic inflammation still occurs in animal models of asthma under disruption or neutralization of CCR3 as well as CCL11 (6) (7) (8) (9) (10) . Furthermore, Yang et al. (11) found no difference in the recruitment of eosinophils between CCL11-intact and -deficient mice, using several models of inflammation. Humbles et al. (9) demonstrated up-regulation of antigen-induced bronchial hyperresponsiveness (BHR) in CCR3-knockout mice. Above all, the lack of a selective antagonist against CCR3 that is available for in vivo administration has confounded accurate assessment of the clinical efficacy of CCR3 blockers to treat allergic disorders. A number of CCR3 antagonists have been investigated (2) , though most of them are peptides/proteins. Recently, the potent, selective, low-molecular weight CCR3 antagonists, SB-297006 and SB-328437, were identified (12) . These compounds inhibit CCL11-induced Ca 2+ mobilization and eosinophil chemotaxis in vitro. The selectivity of these compounds was confirmed using panels of chemokines and other seven-transmembrane receptors (12) .
In order to delineate the role of CCR3 in the development of allergic inflammation in more detail, an antigen-induced murine airway inflammation model, separately initiated by T h 1 and T h 2, was employed in this study, with monitoring of the migration of inflammatory cells including antigen-specific T cells. The contribution of CCR3 and its ligands to T h 1-and T h 2-mediated cellular mobilization in the lungs and BHR was examined using these selective low-molecular weight antagonists and blocking antibodies.
Methods

In vitro polarization of T cells
Ovalbumin (OVA)-specific naive CD4
+ T cells were isolated from the spleen of mice expressing the transgene for DO11. 10 TCRab by a combination of negative and positive selection using a CD4 + T cell isolation kit and CD62L microbeads, respectively, with a magnetic cell sorting system (Miltenyi, Bergisch Gladbach, Germany). Cells were cultured in AIM-V medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) in the presence of 100 lg ml À1 OVA, 10 U ml À1 recombinant IL-2 (BD Biosciences, San Jose, CA, USA) and X-ray-irradiated splenocytes of BALB/c mice. For T h 1 phenotype development, 10 U ml À1 recombinant murine IL-12 (PeproTech, Rocky Hill, NJ, USA) and 1 lg ml À1 neutralizing anti-IL-4 mAb (BD Biosciences) were added and for T h 2 phenotype development, 10 U ml À1 recombinant murine IL-4 (PeproTech) and 1 lg ml À1 anti-IL-12 mAb (BD Biosciences) were used. Seven to ten days after stimulation, cells were harvested, purified by centrifugation over Ficoll-Paque (GE Healthcare Bio-Sciences, Uppsala, Sweden) and then used as T h 1 and T h 2. To determine the integrity of polarization, cells were activated by plate-bound anti-CD3 mAb (145-2C11; BD Biosciences) for 24 h at 37°C in a 5% CO 2 -humidified incubator. For antibody immobilization, wells of culture plates were pre-incubated with 10 lg ml À1 anti-CD3 mAb in 0.05 M carbonate-bicarbonate buffer (pH 9.6) at 4°C overnight. The resulting culture supernatants were collected and subjected to measurement of cytokine and chemokine levels by ELISA.
CCR expression in T cells
Naive and differentiated T cells were re-suspended (10 6 ml À1 ) in AIM-V medium containing 10% FBS and either left unstimulated or stimulated with plate-bound anti-CD3 mAb. After 8 h, cells were harvested and total RNA was then extracted and reverse transcribed using oligo(dT)12-18 primer and ReverTra ACEâ (Toyobo, Osaka, Japan). Quantitative realtime reverse transcription (RT)-PCR was performed using Assay-on-Demand TM Gene Expression products (TaqManâ MGB probes) with an ABI prism 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA). Transcripts of CCR3, CCR4, CCR5, CCR8 and CXC chemokine receptor (CXCR)-3 were normalized to 18S rRNA abundance. In some experiments, the expression of CCR3 on the surface of T h 2 was determined by flow cytometry upon staining with an anti-CCR3 antibody (R&D systems) or isotype-matched control antibody.
Chemotaxis assay
Chemotaxis of T h 2 was measured using 24 transwells with polycarbonate membranes (3 lm; Corning Incorporated, Corning, NY, USA). Chemokines were diluted in 0.6 ml chemotaxis buffer (RPMI 1640 medium containing 0.5% BSA) and added to the lower chemotaxis chamber. T h 2 (10 6 ) were re-suspended in 0.1 ml chemotaxis buffer and added to the top chamber insert. Chemotaxis plates were then incubated for 2 h. After incubation, the cells from the bottom well were collected and counted by flow cytometry.
Cell transfer and challenge procedures
Before transfer, polarized T h 1 and T h 2 were stained with a fluorescein-based dye, 5-(and 6-)-carboxyfluorescein diacetate succinimidyl ester (Molecular Probes, Eugene, OR, USA), as described previously (13) . Twenty-four hours after cell transfer, mice were challenged with aerosolized 10% OVA dissolved in 0.9% saline. In some experiments, the same challenge was performed 1 week after the first challenge. For blocking studies, SB-297006 [(S)-ethyl-2-benzoylamino-3-(4-nitrophenyl)propionate] or SB-328437 [(S)-methyl-2-napthoylamino-3-(4-nitrophenyl)propionate], synthesized in the Discovery Research Laboratory of Tanabe Seiyaku Co., Ltd (Osaka, Japan), suspended in PBS containing 0.1% Tween 80, was administered subcutaneously. The dose of the compounds was determined as 100 mg kg À1 , since both agents displayed a slight sedative effect in mice that received more than this dose (data not shown). A rabbit anti-CCL7 or anti-CCL11 antibody (PeproTech) dissolved in PBS was administered intravenously 30 min before OVA challenge. The vehicle alone did not affect any parameter examined (data not shown). Cellular infiltration in the lungs was examined by bronchoalveolar lavage (BAL) as described previously (13, 14) . BHR was assessed as the degree of bronchoconstriction following infusion of 300 lg kg À1 acetylcholine, at which the maximum difference in respiratory overflow volume between specific antigen-and BSA-challenged animals was obtained, according to the method described previously (14) . We have demonstrated that the cellular profile in BAL fluid well reflects the pathological features and resultant BHR developed in the lungs of T h 2-transferred mice (13, 14) .
Cytokine ELISA
Purified rat anti-mouse IL-5 mAb (TRFK-5; BD Biosciences) and anti-mouse CCL7 antibody (R&D Systems) were used as the capture antibodies and biotinylated rat anti-mouse IL-5 mAb (TRFK4; BD Biosciences) and goat anti-mouse CCL7 antibody (R&D Systems) as the detection antibodies for ELISA. IL-4 and IFN-c were assayed using Duo Setâ (Genzyme, Cambridge, MA, USA), CCL2 using OptEIA TM mouse MCP-1 set (BD Biosciences) and CCL11 using a Quantikineâ M mouse eotaxin immunoassay kit (R&D Systems), according to the manufacturer's instructions.
Statistics
Statistical analysis was performed using one-way analysis of variance with Bonferroni's method. P < 0.05 was considered to indicate statistical significance.
Results
Characterization of in vitro-differentiated T cells
The first experiment was carried out to verify successful polarization of DO11.10 T cells after stimulation culture under the respective conditions for T h 1 and T h 2. As shown in Table 1 , the T h 1 condition facilitated the preferential production of IFN-c but minimal IL-4 and IL-5 upon stimulation with a relevant antigen, whereas the T h 2 condition resulted in a reciprocal pattern. These findings suggest that single stimulation culture under the appropriate condition is sufficient for T h 1-T h 2 differentiation from naive T cells.
We further examined whether naive and differentiated T cells produce chemokines. A CC chemokine, CCL7, was released in the culture supernatant of antigen-stimulated naive DO11.10 T cells and its production was enhanced after T h 1-T h 2 differentiation. The amount of CCL7 produced by T h 2 was three times higher than that by T h 1. The other CC chemokines, CCL2 and CCL11, were not detectable in any condition examined (Table 1) .
It has been documented that CCR3 is preferentially expressed in T h 2 of human origin (7, 15, 16) , though its expression pattern in murine T h has not been fully characterized. Therefore, the expression of CCR3 and other T h 1/T h 2-specific chemokine receptors in DO11.10 T cells was next determined by a quantitative real-time RT-PCR. As shown in Fig. 1(A) , CCR3 was significantly expressed in naive T cells and was slightly up-regulated by stimulation through TCR. Both basal and inducible expression levels of CCR3 were minimally affected by T h 1 and T h 2 differentiation. On the other hand, the expression of CCR4 in T h 2 was much higher than that in T h 1 and naive T cells, while CCR8 was specifically induced in T h 2 upon stimulation. In contrast, CCR5 and CXCR3 were highly up-regulated following stimulation in T h 1, but not in naive or T h 2 (Fig. 1A) . Flow cytometric analysis further revealed that CCR3 was weakly but definitely expressed on the surface of T h 1 and T h 2 (Fig. 1B) .
Effects of CCR3 antagonists on chemotaxis of T h 2 in vitro
The CCR3 antagonist, SB-328437, has been reported to block human eosinophil chemotaxis evoked by CCL11, CCL13 and CCL24 with similar potencies (IC 50 values of 32, 25 and 55 nM, respectively) (12) . However, the effect of a CCR3 antagonist on chemotaxis of murine cells has not been evaluated well. In order to elucidate whether CCR3 antagonists interfere with the murine CCR3/CCR3 ligandmediated response, the effects of structurally related agents, SB-297006 and SB-328437, on CCL11-induced chemotaxis Naive and T h 1/T h 2-differentiated DO11.10 T cells (5 3 10 5 per ml) were either let unstimulated or stimulated with plate-bound anti-CD3 mAb. After 24 h, the concentrations of cytokines in the culture supernatants were measured by ELISA. Data are the means of quadruplicate cultures (standard error of the mean <10%) of T h 2 were examined. On average, ;10% of T h 2 migrated in response to CCL11, though no significant chemotactic response was observed in naive or T h 1 (data not shown). SB-297006 and SB-328437 suppressed CCL11-induced T h 2 chemotaxis, with IC 50 values of 2.5 and 10 lM, respectively (Fig. 2) . The inhibitory effects of these compounds on CCL11-induced T h 2 chemotaxis were selective, as they failed to affect CCL17-induced migration of T h 2 even at 10 lM (Fig. 2) .
Effects of CCR3 antagonists on T h 1-and T h 2-mediated cellular mobilization in lung
The role of CCR3 in T cell-mediated leukocyte accumulation was examined in vivo using its selective antagonists. In mice that underwent transfer of T h 1-and T h 2-polarized DO11.10 T cells, migration of antigen-specific T cells themselves in the lungs was detectable upon inhalation challenge with OVA (Fig. 3) . Subsequently, massive accumulation of neutrophils occurred in T h 1-transferred mice, whereas eosinophil infiltration was specifically induced by T h 2, consistent with previous findings (17) (18) (19) (20) . The migration of neutrophils and eosinophils was dependent on infused T cells and their specific antigen, since they failed to infiltrate the lungs of BSAchallenged mice. In addition, OVA challenge to unprimed mice, even when it was performed twice with 1-week interval, did not affect any parameter examined. SB-297006 and SB-328437 suppressed antigen-induced accumulation of eosinophils as well as antigen-specific T cells in T h 2-transferred mice (Fig. 3A) . In contrast, infiltration of T cells and neutrophils in T h 1-transferred mice was not affected by these agents.
Next, the effects of CCR3 antagonists were compared with those of specific antibodies against CCR3-related chemokines. Antigen-induced migration of T cells as well as eosinophils in T h 2-transferred mice was suppressed by treatment with antibodies against CCL7 and CCL11 (Fig. 3B ). An anti-CCL11 antibody also inhibited the migration of T h 1 and, less potently, neutrophils in T h 1-transferred mice. Non-specific control antibody failed to affect cellular infiltration in T h 1-and T h 2-transferred mice (Fig. 3B) . These findings clearly suggest that a CCL11-CCR3 interaction is required for the accumulation of antigen-induced T h 2 and eosinophils in the lungs.
Effects of CCR3 antagonists on T h 1-and T h 2-mediated cytokine production in lung
Recent investigations demonstrated that neutralization of chemokines potentially affects the synthesis of cytokines and chemokines themselves in vivo (21) . Therefore, the effects of CCR3 antagonists on cytokine production in the lungs were next determined. The concentrations of T h 2 cytokines, IL-4 and IL-5, a T h 1 cytokine, IFN-c, and CC chemokines, CCL2, CCL7 and CCL11, in the BAL fluid of T h 1-and T h 2-transferred mice were measured by ELISA. As shown in Fig. 4 , IFN-c was specifically produced in the lungs of T h 1-transferred mice upon challenge with a relevant antigen. On the other hand, IL-4 and IL-5 were preferentially produced by T h 2, while CCL2, CCL7 and CCL11 were produced in both T h 1-and T h 2-transferred mice. T h 2-mediated IL-4 and IL-5 production in vivo was minimally attenuated, if at all, by treatment with SB-297006 and SB-328437 (Fig. 4) , even though they suppressed the migration of antigen-specific T h 2 (Fig. 3) . The CCR3 antagonists did not affect any cytokine production in the lungs of T h 1-transferred mice (Fig. 4) .
In contrast, blocking of CCR3 by its antagonists effectively attenuated the production of CCL2, CCL7 and CCL11 only in the lungs of T h 2-transferred mice (Fig. 4) , suggesting that a reduction of chemokine production participates in the selective suppression of T h 2-mediated cellular mobilization by CCR3 antagonists.
Effects of CCR antagonist on T h 2-mediated BHR
Our present findings suggest that CCR3 blockers will be effective to treat allergic diseases associated with eosinophilic inflammation. However, the role of CCR3 in the change of airway function due to eosinophilic inflammation is controversial. Therefore, our next investigation was performed to evaluate the effect of a CCR3 antagonist on antigen-induced BHR in T cell-transferred mice. Single administration of OVA Fig. 2 . Effects of CCR3 antagonists on chemotactic activity of T h 2. Chemotaxis of T h 2 was induced by 100 nM CCL11 or CCL17 in the presence of SB-297006 or SB-328437. Data are expressed as mean 6 SEM of quadruplicate cultures. *P < 0.05, compared with ligand alone-stimulated control.
failed to produce significant BHR in mice transferred with T h 1-and T h 2-differentiated DO11.10 T cells (data not shown). However, bronchial responsiveness to acetylcholine was clearly up-regulated in T h 2-transferred mice upon second antigen challenge 1 week after the first challenge (Fig. 5B) . Accordingly, a 4-fold larger number of eosinophils accumulated in the lungs (Fig. 5A) , compared with that after a single challenge (Fig. 3) . As shown in our previous investigations (14) , BHR peaked at 96 h after the second challenge and was not observed in T h 1-or naive T cell-transferred mice (data not shown).
The effects of CCR3 antagonists and an anti-CCL11 antibody were examined in this experimental system. As shown in Fig. 5 , antigen-induced accumulation of eosinophils in the lungs as well as BHR was significantly suppressed by an anti-CCL11 antibody. Although the effect of SB-297006 was not statistically significant in the present experiments, this compound may be weakly inhibitory to both reactions. SB-328437 failed to affect antigen-induced lung eosinophilia and BHR, according to the relative low potency of this compound to suppress CCL11-induced T h 2 chemotaxis in vitro (Fig. 2) .
Discussion
The contribution of CCR3 to the development of allergic eosinophilic inflammation has been investigated in vivo using gene-disrupted animals and/or neutralizing antibodies against CCR3 and CCR3 ligands, especially CCL11 (6-9, 22). Nevertheless, the potential of CCR3 antagonists to treat allergic disorders associated with eosinophilic inflammation remains unclear. We here evaluated the effects of CCR3 antagonists on allergic airway inflammation models separately induced by antigen-specific T h 1 and T h 2. CCR3 specifically participated in antigen-induced migration of T h 2 and eosinophils in the lungs. Further, suppression of chemokine synthesis was suggested to be involved in the mechanism by which a CCR3 antagonist attenuated T h 2-mediated eosinophil accumulation in the lungs.
A number of investigations have demonstrated that T h 1 and T h 2 express distinct sets of chemokine receptors: T h 1 preferentially express CCR5 and CXCR3, while CCR3, CCR4 and CCR8 are dominantly expressed on T h 2 (2, 3, 7, 15, 16), even though several reports conflict with this statement (23) (24) (25) (26) . Our present findings generally agree with these investigations, whereas the expression of CCR3 in murine T h was not strongly affected by their polarization status and stimulation (Fig. 1 ). The present results are supported by Bonecchi et al. (15) who reported that the difference between the expression of CCR3 in T h 1 and T h 2 was much smaller than that of CCR4, CCR5 and CXCR3. Lloyd et al. (7) found differential expression of CCR3 after three-round stimulation culture under a T h 1-T h 2 differentiation condition, whereas we confirmed that CCR3 expression on T h 2 was not up-regulated even after two additional round stimulation culture ( Supplementary Fig. 1 , available at International were stained with 5-(and 6-)-carboxyfluorescein diacetate succinimidyl ester (CFSE) and transferred to normal mice by intravenous injection. After 24 h, these mice were challenged with inhaled 10% OVA or BSA for 60 min. BAL was performed 48 h after challenge and the numbers of neutrophils and eosinophils in BAL fluid were counted in T h 1-and T h 2-transferred mice, respectively. The number of CFSE-positive cells was also determined by flow cytometry. CCR3 antagonists (100 mg kg À1 ) were administered subcutaneously (A) and neutralizing antibodies (20 mg kg À1 ) were administered intravenously (B) 30 min before OVA challenge. *P < 0.05, **P < 0.01, compared with OVA-challenged control animals (n = 4-12).
Immunology Online). Therefore, further investigation will be required to clarify the relationship between the polarization status and CCR3 expression property of T cells.
Nevertheless, a functional difference in CCR3 expressed on T h 1 and T h 2 was observed in the present study (Fig. 3) , even though CCL11 as well as CCL7 was equivalently produced in vivo (Fig. 4) . The reason for the discrepancy between the expression and function of CCR3 in T h 1-T h 2 is not clear, but it is potentially due to a difference in signaling cascades through this receptor. CCR3 is a seven-transmembrane domain G protein-coupled receptor, and the interaction of CCR3 with its ligands evokes Ca 2+ influx (27, 28) . It has been reported that the Ca 2+ mobilization pattern is different in T h 1 and T h 2, even though it is in the case that T cells are stimulated through TCR but not through CCR3 (29, 30) . Therefore, signaling events through CCR3 in T h 1-T h 2 remain to be further analyzed. Our present data that CCR3 antagonists specifically suppressed T h 2-mediated airway eosinophilic infiltration not only indicate the clinical efficacy of CCR3 antagonists against allergic disorders but also suggest that they do not exhibit undesirable side effects, at least due to the suppression of T h 1-mediated host defense activity against numerous infectious pathogens.
Neutralization of CCL11, which utilizes CCR3, resulted in the attenuation of not only T h 2-mediated cellular mobilization but also T h 1 migration and subsequent infiltration of neutrophils, whereas an antibody against CCL7, another ligand for CCR3, specifically suppressed the accumulation of T h 2 and eosinophils. The reason why antibodies against two CCR3 ligands showed different effects on T h 1-mediated airway inflammation is not clear. However, it has been suggested that CCR5 as well as CCR2 acts as a receptor for CCL11 (31, 32) , while CCL7 associates with CCR1 and CCR2 (4). Like CXCR3, CCR5 was preferentially expressed on T h 1 (2; Fig. 1) , suggesting that the engagement of CCR5 with CCL11 potentially participates in the migration of T h 1. As no chemokine that interacts with CCR5 alone has been identified, further examination using CCR5 antagonists as well as CCR5-deficient animals is required to elucidate the functional role of CCR5 in T h 1-mediated allergic inflammation.
Two structurally related CCR3 antagonists exhibited their specific activity against murine T h 2 in vitro. Thus, SB-297006 and SB-328437 suppressed T h 2 chemotaxis induced by CCL11 but not CCL17 (Fig. 2) . However, the effective dose range of these compounds (IC 50 = 2.5 and 10 lM) was much higher than that investigated by White et al. (12) employing human eosinophils (IC 50 = 3.3 nM for SB-328437). The relative weakness of CCR3 antagonists to suppress chemotaxis of murine cells, compared with that of human cells, may have been due to species specificity of the compounds. In fact, White et al. (12) reported that the effects of CCR3 antagonists on CCL11/CCR3 binding of murine and guinea pig origin were much weaker than that of human origin. Our present findings are consistent with their ) were administered subcutaneously 30 min before OVA challenge. *P < 0.05, **P < 0.01, compared with OVA-challenged control animals (n = 4-6).
report, and further indicate that SB-297006 and SB-328437 selectively interfere with CCL11-mediated migration of murine T h 2.
CCR3 antagonists failed to affect IL-4 and IL-5 production in the lungs (Fig. 4) , even though they suppressed the migration of antigen-specific T h 2 cells (Figs 2 and 3) . In addition, we have demonstrated that the production of cytokines in the lungs of T cell-transferred mice preceded the accumulation of T cells (13, 17) , suggesting that a small number of antigen-specific T cells that were infused and spontaneously distributed in the lungs before antigen challenge were the predominant source of T h 1-T h 2 cytokines. In contrast, blocking of CCR3 by its antagonists effectively attenuated the production of CCR3-related and -unrelated chemokines only in the lungs of T h 2-transferred mice (Fig. 4) , suggesting that a reduction in chemokine production participates in the selective suppression of T h 2-mediated cellular mobilization by CCR3 antagonists. T cells employed for adoptive transfer have the capacity to produce CCL7 but not CCL2 and CCL11 in vitro (Table 1) . Therefore, antigen-specific T cells existing in the lungs are unlikely to produce most of the chemokines detected. The exact sources of those chemokines were not identified in the present study; however, mRNA and protein expression of CCR3-ligands has been detected in many different cell types at sites of inflammation (2, 33, 34) . Resident cells such as epithelial cells, fibroblasts and endothelial cells have been shown to produce significant levels of such chemokines upon activation (34) (35) (36) (37) . Although infused T cells could produce CCL7 in vitro (Table 1) , it has been shown that this chemokine is predominantly released by airway epithelial cells in vivo, which also express CCR3 (33, 38) . In addition, the existence of a regulatory cascade by which chemokines induce the synthesis of chemokines themselves has been suggested. Thus, an anti-CCL17 mAb inhibited the expression of CCL11 mRNA in the lungs of a murine model of asthma (21) . Taking these findings together, CCR3-active chemokines, including CCL7, initially released by infused T cells upon antigen challenge may evoke explosive production of a variety of chemokines by airway epithelial cells and other cell types. CCR3 antagonists potentially inhibited the engagement of CCR3 ligands to their receptors on chemokine-releasing cells including airway epithelial cells, and subsequently, massive chemokine synthesis by those cells might be attenuated.
Nevertheless, the contribution of CCR3 to chemokine production in the lungs of T h 1-transferred mice was negligible (Fig. 4) . In the case of T h 1-mediated responses, the interaction of a T h 1-specific chemokine and its receptor other than CCR3 or IFN-c by itself might play a major role in the synthesis of a variety of chemokines in vivo. Further studies will be required to elucidate additional details of the mechanism by which CCR3 antagonists suppressed chemokine production specifically in T h 2-transferred mice.
The development of BHR in T h 2-transferred mice was weakly and significantly suppressed by SB-297006 and anti-CCL11 antibody, respectively (Fig. 5) , though the inhibitory potency of CCR3 antagonists and anti-CCL11 antibody was lower than that observed in Fig. 3 . It could be explained, at least in part, by the relative severity of the inflammatory response that occurred upon repeated antigen provocation. On the other hand, the lower potency of CCR3 antagonists, compared with that of an antibody against CCL11, may be due to a difference in the stability of chemical compounds and antibody in mice. We have found that the blood concentration of SB-297006 was already below its in vitro effective dose range 24 h after the administration (data not shown), whereas Ig is one of the most stable proteins in serum and injected anti-CCL11 antibody probably neutralized CCL11 for several days or weeks.
Several contradictory findings have been reported regarding the role of CCR3 in BHR. Ma et al. (10) demonstrated that antigen-induced BHR in epicutaneously immunized mice was abolished by gene disruption of CCR3, though Humbles et al. (9) from the same group observed enhancement of BHR in CCR3 À/À mice sensitized by intra-peritoneal antigen injection. The reason for the discrepancy was were transferred to normal mice by intravenous injection. On days 1 and 7, these mice were challenged with inhaled 10% OVA or BSA for 60 min. Assessment of bronchoconstriction induced by the infusion of acetylcholine (300 lg kg À1 ), and BAL were performed 96 h after the second challenge. SB-297006 (100 mg kg
À1
) and an anti-CCL11 antibody (20 mg kg À1 ) were administered subcutaneously and intravenously, respectively, 30 min before each OVA challenge. *P < 0.05, compared with OVA-challenged control animals (n = 4-12).
explained by the contribution of mast cells; thus, antigen-induced mast cell mobilization into the airway epithelium was increased in intra-peritoneally sensitized CCR3 À/À mice (9), but not in epicutaneously immunized CCR3 À/À mice (10). The contribution of mast cells in our experimental system employed in this study seems to be low, since there is no process to synthesize antigen-specific IgE. In this condition, we have demonstrated that the intensity of BHR was significantly correlated with the number of eosinophils accumulated in the lungs (14) . Further examination will be required to elucidate the effects of CCR3 antagonists on mast celldependent responses; however, the present study suggests that these agents are potentially effective against antigeninduced BHR, at least that mediated by T h 2. As the most recent report suggested that CCR3 is involved in dysfunction of the M2 muscarinic receptor in a guinea pig asthma model (39) , the relationship between cellular and neuronal inflammation, both in which CCR3 is implicated, should be next investigated.
In conclusion, we demonstrated that CCR3 selectively participates in the induction of T h 2-mediated infiltration of eosinophils as well as T cells themselves in the lungs. CCL11 contributes to airway inflammation initiated by both T h 1 and T h 2. Specific CCR3 antagonists, that attenuate the migration of T h 2 and eosinophils, can potentially be used to treat allergic diseases.
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